Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy

Centre Hospitalier Universitaire de Saint Etienne

Status: Completed

Conditions: IGA Glomerulonephritis

Treatments: Device: Holter

Study type: Interventional

Funder types: Other

Identifiers

NCT02527902

1008123

Details and patient eligibility

About

The estimation of the cardiovascular risk in the general population must take into account small renal disturbances, as the microalbuminuria. Conversely certain parameters of the cardiovascular risk influence the evolution of renal diseases, for example the arterial high blood pressure.

The measure of the activity of the autonomous nervous system, and especially the quantification of its variability, is a means to estimate the cardiovascular risk. The investigators formulate the hypothesis that the variability of the autonomous nervous system is an additional clinical element for the evaluation of the evolutionary risk of renal diseases.

The aim of this study is to compare the variability of the autonomous nervous system during the various evolutionary stages of the renal disease.

The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at list 1+) by immunofluorescence.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of IgNA biopsy-proven free, informed, express and written

Exclusion criteria

• IgNA secondary to Henoch-Schonlein purpura (HSP) or Systemic Lupus Erythematosus or alcoholic cirrhosis
• current kidney transplantation
• Hypertension treated or not,
• Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy
• diabetes

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

12 participants in 5 patient groups

IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2

Experimental group

Description:

Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) \>90 ml/min/1.73 m2

Treatment:

Device: Holter

IgAN with GFR 60-89 ml/min/1.73 m2

Experimental group

Description:

Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2

Treatment:

Device: Holter

IgAN with GFR 30-59 ml/min/1.73 m2

Experimental group

Description:

Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2

Treatment:

Device: Holter

IgAN with GFR 15-29 ml/min/1.73 m2

Experimental group

Description:

Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2

Treatment:

Device: Holter

IgAN with GFR < 15ml/min/1.73 m2

Experimental group

Description:

Measure of ANS by holter device in IgAN patients with GFR \< 15ml/min/1.73 m2.

Treatment:

Device: Holter